Literature DB >> 24014214

Clomiphene citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial.

Mohamad E Ghanem1, Laila A Elboghdady, Mohamad Hassan, Adel S Helal, Ahmed Gibreel, Maha Houssen, Mohamed E Shaker, Ibrahiem Bahlol, Yaser Mesbah.   

Abstract

PURPOSE: The aim of this study was to examine the effect of clomiphene citrate [CC] co-administration during the use of exogenous low-dose urinary FSH [uFSH] for induction of ovulation in CC-resistant infertile PCOS women.
METHODS: In a randomised controlled setting, 174 CC-resistant infertile PCOS women were randomized into two parallel groups; Group I received CC 100 mg/day for 5 days plus uFSH 37.5 IU/day while group II received only uFSH 37.5 IU /day. Subsequent increments of uFSH by 37.5 IU/day were made according to response. Primary outcome was ovulation rate. Secondary outcomes were clinical pregnancy rates, number of follicles, endometrial thickness, and gonadotropins consumption.
RESULTS: Our results have demonstrated that group I compared to group II had significantly higher ovulation rate per intention to treat [ITT] [72.4 % vs. 34.2 %, p < 0.001]. Clinical pregnancy and live birth rates were comparable between the two groups. Group I consumed significantly lower total FSH dose and needed significantly shorter stimulation duration compared to group II.
CONCLUSION: CC co-administered during low dose HP uFSH versus uFSH for CC-resistant PCOS yields significantly higher ovulation rate and less consumption of FSH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24014214      PMCID: PMC3879942          DOI: 10.1007/s10815-013-0090-2

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  23 in total

Review 1.  Best practices of ASRM and ESHRE: a journey through reproductive medicine.

Authors:  L Gianaroli; C Racowsky; J Geraedts; M Cedars; A Makrigiannakis; R Lobo
Journal:  Hum Reprod       Date:  2012-10-23       Impact factor: 6.918

2.  Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol.

Authors:  J Balasch; F Fábregues; M Creus; R Casamitjana; B Puerto; J A Vanrell
Journal:  J Assist Reprod Genet       Date:  2000-11       Impact factor: 3.412

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen.

Authors:  P Trinder
Journal:  J Clin Pathol       Date:  1969-03       Impact factor: 3.411

5.  Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2.

Authors:  G Assmann; H Schriewer; G Schmitz; E O Hägele
Journal:  Clin Chem       Date:  1983-12       Impact factor: 8.327

6.  Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin.

Authors:  D Hamilton-Fairley; D Kiddy; H Watson; C Paterson; S Franks
Journal:  Br J Obstet Gynaecol       Date:  1992-02

7.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

Review 8.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

Authors: 
Journal:  Hum Reprod       Date:  2004-01       Impact factor: 6.918

9.  Sequential clomiphene citrate and human menopausal gonadotrophin for ovulation induction: comparison to clomiphene citrate alone and human menopausal gonadotrophin alone.

Authors:  R P Dickey; T T Olar; S N Taylor; D N Curole; P H Rye
Journal:  Hum Reprod       Date:  1993-01       Impact factor: 6.918

10.  Characteristics of the best prognostic evidence: an example on prediction of outcome after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility.

Authors:  M J C Eijkemans; J D F Habbema; B C J M Fauser
Journal:  Semin Reprod Med       Date:  2003-02       Impact factor: 1.303

View more
  4 in total

1.  Comment on: "Clomiphene Citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial." by Ghanem et al.

Authors:  A Papathanasiou
Journal:  J Assist Reprod Genet       Date:  2013-10-26       Impact factor: 3.412

2.  Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility.

Authors:  M F Costello; M L Misso; A Balen; J Boyle; L Devoto; R M Garad; R Hart; L Johnson; C Jordan; R S Legro; R J Norman; E Mocanu; J Qiao; R J Rodgers; L Rombauts; E C Tassone; S Thangaratinam; E Vanky; H J Teede
Journal:  Hum Reprod Open       Date:  2019-01-04

3.  Use of letrozole and clomiphene citrate combined with gonadotropins in clomiphene-resistant infertile women with polycystic ovary syndrome: a prospective study.

Authors:  Wenyan Xi; Shankun Liu; Hui Mao; Yongkang Yang; Xiang Xue; Xiaoning Lu
Journal:  Drug Des Devel Ther       Date:  2015-11-11       Impact factor: 4.162

4.  Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial.

Authors:  Batool Hossein-Rashidi; Bahareh Khandzad; Ensieh Shahrokh-Tehraninejad; Maryam Bagheri; Mansoureh Gorginzadeh
Journal:  J Family Reprod Health       Date:  2016-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.